Development of Technology Sample Clauses

Development of Technology. The Licensor agrees to assist the Licensee to conclude the negotiations on technologies under consideration as set out in Exhibit A1, "Properties."
Sample 1Sample 2Sample 3See All (5)
AutoNDA by SimpleDocs
Development of Technology. Licensee shall use its best reasonable efforts to complete an initial working prototype of the Licensed Product for Phase I no later than November 1, 1998.
Sample 1
Development of Technology. Base Ten hereby agrees, during the Term of this Agreement, to complete the development of the Technology, and to submit to the LLC quarterly reports in connection with the progress of such development and the costs (as hereinafter defined) incurred by Base Ten.
Sample 1
Development of Technology. As a condition to Closing, the Company shall complete the development of a tocotrienol processing technology for use with palm oil distillate and similar fatty acid stream derived from rice bran oil deodorization or other biological fatty acid source (collectively "Feed"), that includes a pre-concentration method, and any and all intellectual property relating thereto ("Technology"). The Company shall develop the Technology in sufficient detail for the Sellers to file a patent application and to allow the Sellers reasonably to communicate cost, operation, and method of the Technology to a third party. Upon transfer of the Technology to the Sellers, the Technology shall be the exclusive property of the Sellers to use freely in their respective sole discretion, without further compensation to the Company or Purchaser. The Parties acknowledge that each has a desire to cooperate after the Closing and the transfer of the Technology to design, fabricate and install an operating system based on the Technology for the processing of Feed.
Sample 1
Development of Technology. Continue to diligently pursue the development of the Technology in accordance with the Company's current plans (as described to Acquiror), including, but not limited to: (i) continued funding of the development efforts in the laboratory of Xxxx X. Xxxxxxxxx, M.D.; (ii) continued payments to the Company's consultants, (subject to the other provisions of this Section 5.1); and (iii) continuation of the U.S. Phase III clinical trial of CBP-1011.
Sample 1
Development of Technology has no obligation to share with the University of Maine or others details on the performance of any technology pertaining to the Licensed Products or Licensed Patents technology, e.g., data and process information. The University of Maine has no right, without _________ prior written approval, to release any press release or other publicity or advertising which mentions __________ by name or otherwise identifies _______, except as required by Maine State law. This agreement does not grant to the University of Maine any rights to ________ developed advances, whether or not patentable. The University of Maine shall not be liable for any costs incurred by __________ during the development of this any technology pertaining to the Licensed Products or Licensed Patents.
Sample 1
Development of Technology 
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs

Related to Development of Technology

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Joint Technology The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

  • Licensed Technology The term "Licensed Technology" shall mean the ------------------- Licensed Patents, plus all improvements thereto developed by Licensor, and all related data, know-how and technology.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

Time is Money Join Law Insider Premium to draft better contracts faster.